38 completed, 8 recruiting, 2 active not recruiting, 2 terminated. 19 Phase 3, 16 Phase 1, 14 Phase 2, 3 Early Phase 1, 1 Not applicable.
Follow Zealand Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Petrelintide, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 3 | Recruiting | Hoffmann-La Roche | 600 | 2026-09-30 | 2026-10-07 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity Petrelintide, Placebo - Obesity or Overweight | Phase 3 | Recruiting | Hoffmann-La Roche | 3900 | 2026-09-30 | 2026-10-07 |
| A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight Petrelintide, Enicepatide, Petrelintide-matching Placebo - Obesity or Overweight | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 486 | 2026-09-30 | 2026-09-09 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease Petrelintide, Placebo - Obesity or Overweight, Cardiovascular Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 2500 | 2026-09-30 | 2026-10-07 |
| A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period ZP9830, Placebo - Plaque Psoriasis | Phase 1 | Recruiting | Zealand Pharma | 32 | 2026-07-22 | 2026-07-29 |
| A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity ZP6590, solution for injection, Placebo, solution for injection - Healthy Participants Study, Overweight and Obese Adults | Early Phase 1 | Recruiting | Zealand Pharma | 88 | 2026-07-09 | 2026-08-13 |
| Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function Petrelintide - Impaired Hepatic Function | Phase 1 | Recruiting | Zealand Pharma | 36 | 2026-05-18 | 2026-07-06 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Recruiting | Zealand Pharma | 90 | 2026-02-11 | 2026-09-29 |
| Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations Petrelintide - Obesity & Overweight | Phase 1 | Completed | Zealand Pharma | 48 | 2025-12-17 | 2026-04-08 |
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome Glepaglutide 10 mg - Short Bowel Syndrome (SBS) | Phase 3 | Active not recruiting | Zealand Pharma | 28 | 2025-12-11 | 2026-07-30 |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) Petrelintide, Placebo - Overweight, Type 2 Diabetes | Phase 2 | Completed | Zealand Pharma | 221 | 2025-04-22 | 2026-09-09 |
| Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function Petrelintide - Renal Impairment | Phase 1 | Completed | Zealand Pharma | 39 | 2025-04-15 | 2026-01-28 |
| A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Dapiglutide 7.5 mg - Overweight and Obesity | Phase 1 | Completed | Zealand Pharma | 30 | 2024-12-23 | 2025-05-06 |
| Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities Petrelintide, Placebo - Obesity | Phase 2 | Completed | Zealand Pharma | 493 | 2024-12-09 | 2026-03-23 |
| A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants ZP9830, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Zealand Pharma | 124 | 2024-11-12 | 2026-02-17 |
| A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 ZP7570, Placebo - Safety and Tolerability | Phase 1 | Terminated | Zealand Pharma | 84 | 2023-09-15 | 2025-04-25 |
| A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Dasiglucagon - Hypoglycemia, Type 1 Diabetes | Phase 3 | Completed | Zealand Pharma | 8 | 2023-05-09 | 2025-07-20 |
| Dapiglutide for the Treatment of Obesity Dapiglutide, Placebo - Obesity, Inflammation | Phase 2 | Active not recruiting | University Hospital, Gentofte, Copenhagen | 54 | 2023-04-27 | 2024-12-05 |
| Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults Dasiglucagon, Placebo - Hypoglycemia, Glucose Metabolism Disorders | Phase 2 | Withdrawn | Zealand Pharma | 2023-02-01 | 2023-02-21 | |
| A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants ZP8396, Drug: Placebo (ZP8396) - Overweight, Healthy Volunteers | Phase 1 | Completed | Zealand Pharma | 68 | 2022-11-07 | 2024-06-18 |
Showing 20 of 52. Sign in to see all of them.
Obesity (13) · Hypoglycemia (12) · Overweight (12) · Diabetes Mellitus, Type 1 (8) · Short Bowel Syndrome (7) · Congenital Hyperinsulinism (4) · Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus (2) · Digestive System Diseases (2) · Gastrointestinal Diseases (2) · Intestinal Diseases (2) · Malabsorption Syndromes (2) · Pathologic Processes (2) · Postoperative Complications (2) · Renal Insufficiency (2)
dasiglucagon (15) · Glucagon (4) · Glucagon-Like Peptide 1 (3) · Injections (2) · Blood Specimen Collection (1) · Insulin Lispro (1) · Restraint, Physical (1) · Sodium Chloride (1) · Solutions (1) · Standard of Care (1) · ZP120 (1) · danegaptide (1)
Germany (25) · United States (23) · Denmark (11) · Poland (8) · Netherlands (7) · United Kingdom (7) · Canada (6) · Belgium (5) · France (5) · Austria (3) · Israel (3) · Hungary (2) · Finland (1) · Italy (1) · Norway (1)
Christina M Sylvest, MSc Pharm (3) · Christina Sylvest, MSc Pharm (2) · Filip K Knop, MD, PhD (2) · Ulrike Hoevelmann, MD (2) · Carsten Dirksen, MD, PhD (1) · Charlotte Teglman Schioeler (1) · Christian Thorkildsen (1) · Gertrud Koefoed Rasmussen, MSc (1)
PMID 29273578, PMID 29602883, PMID 30880176, PMID 31326433, PMID 31949084, PMID 33906916, PMID 34287979, PMID 35239971, PMID 35464292, PMID 36323988, PMID 36576342, PMID 36811175, PMID 39708985, PMID 41768273, PMID 42810355
2019 (3), 2025 (2), 2017 (1), 2023 (1)